Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry.

作者: Michael G. Feasel , Ariane Wohlfarth , John M. Nilles , Shaokun Pang , Robert L. Kristovich

DOI: 10.1208/S12248-016-9963-5

关键词:

摘要: Carfentanil is an ultra-potent synthetic opioid. No human carfentanil metabolism data are available. Reportedly, Russian police forces used and remifentanil to resolve a hostage situation in Moscow 2002. This alleged use prompted interest the pharmacology toxicology of humans. Our study was conducted identify metabolites assess carfentanil’s metabolic clearance, which could contribute its acute toxicity We Simulations Plus’s ADMET Predictor™ Molecular Discovery’s MetaSite™ predict possible metabolite formation. Both programs gave similar results that were generally good but did not capture all seen vitro. incubated with hepatocytes for up 1 h analyzed samples on Sciex 3200 QTRAP mass spectrometer measure parent compound depletion extrapolated represent intrinsic clearance. Pooled primary then 6 identification 5600+ TripleTOF (QTOF) high-resolution spectrometer. MS MS/MS analyses elucidated structures most abundant metabolites. Twelve identified total. N-Dealkylation monohydroxylation piperidine ring dominant pathways. Two N-oxide one glucuronide observed. Surprisingly, ester hydrolysis major pathway carfentanil. While liver microsomal system demonstrated rapid clearance by CYP enzymes, hepatocyte incubations showed much slower possibly providing some insight into long duration effects.

参考文章(30)
Janssen Pa, Van Bever Wf, Niemegeers Cj, Schellekens Kh, N-4-Substituted 1-(2-arylethyl)-4-piperidinyl-N-phenylpropanamides, a novel series of extremely potent analgesics with unusually high safety margin. Drug Research. ,vol. 26, pp. 1548- ,(1976)
Gary L. Henderson, Designer drugs: past history and future prospects. Journal of Forensic Sciences. ,vol. 33, pp. 569- 575 ,(1988) , 10.1520/JFS11976J
TH Lavé, S Dupin, C Schmitt, B Valles, G Ubeaud, RC Chou, D Jaeck, PH Coassolo, None, The Use of Human Hepatocytes to Select Compounds Based on Their Expected Hepatic Extraction Ratios in Humans Pharmaceutical Research. ,vol. 14, pp. 152- 155 ,(1997) , 10.1023/A:1012036324237
D E Feierman, J M Lasker, Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4 Drug Metabolism and Disposition. ,vol. 24, pp. 932- 939 ,(1996)
Hartmut Burkle, Stuart Dunbar, Hugo Van Aken, Remifentanil: a novel, short-acting, mu-opioid. Anesthesia & Analgesia. ,vol. 83, pp. 646- 651 ,(1996) , 10.1097/00000539-199609000-00038
Colleen A. McNaney, Dieter M. Drexler, Serhiy Y. Hnatyshyn, Tatyana A. Zvyaga, Jay O. Knipe, James V. Belcastro, Mark Sanders, An Automated Liquid Chromatography-Mass Spectrometry Process to Determine Metabolic Stability Half-Life and Intrinsic Clearance of Drug Candidates by Substrate Depletion Assay and Drug Development Technologies. ,vol. 6, pp. 121- 129 ,(2008) , 10.1089/ADT.2007.103
Jérôme Guitton, Thierry Buronfosse, Michel Désage, Alain Lepape, Jean-Louis Brazier, Philippe Beaune, Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil Biochemical Pharmacology. ,vol. 53, pp. 1613- 1619 ,(1997) , 10.1016/S0006-2952(96)00893-3
Carl C. Hug, Michael R. Murphy, Tissue redistribution of fentanyl and termination of its effects in rats Anesthesiology. ,vol. 55, pp. 369- 375 ,(1981) , 10.1097/00000542-198110000-00006
Patricia S. Villemagne, Robert F. Dannals, Hayden T. Ravert, James J. Frost, PET imaging of human cardiac opioid receptors. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 29, pp. 1385- 1388 ,(2002) , 10.1007/S00259-002-0897-Z